The study and its comparison
A randomized trial included 40 participants. The study population was adults with overt type 2 diabetic nephropathy. Researchers compared turmeric 500 mg three times daily, each capsule containing 22.1 mg curcumin, versus starch placebo, with follow-up over two months. [1]
The abstract reports lower urinary protein and selected inflammatory measures after turmeric treatment compared with pretreatment values. It reports no supplement-related adverse effects during the short study. [1]
What the finding establishes
The abstract does not supply clear between-group effect estimates for these changes. Biomarker improvement is not evidence of preventing dialysis or death, and forty participants cannot establish broad kidney safety. Turmeric mass and curcumin mass are different quantities and should not be interchanged. Funding and complete conflicts were not established from the retrieved abstract. [1]
A hypothetical distinction
Imagine a capsule contains 500 mg of plant material but 22.1 mg of its active constituent. Three capsules do not supply 1500 mg of that constituent.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.